Table 4.

Outcomes (during 14-days follow-up) for SARS-CoV-2 positive patients who were eligible for mechanical ventilation. Bonferroni-corrected significance level = .003. Data are shown N (%). Treatment during in-hospitalization and outcomes during 14 days of follow-up among eligible for mechanical ventilation in COVID-19 patients. Furthermore, outcomes according to suPAR cut-offs is shown.

Variable	suPAR ⩽4 ng/mL	suPAR 4-6 ng/mL	suPAR ⩾6 ng/mL	P value
N (%)	28 (38.8)	22 (30.6)	22 (30.6)
Discharged within 24 hours (%)	16 (57.1)	6 (27.3)	5 (22.7)	.0219
Readmitted during follow up (%)	5 (18.5)	2 (10)	2 (10.5)	.629
Still admitted (%)	2 (7.1)	3 (13.6)	8 (36.4)	.0232
Need of oxygen (%)	10 (35.7)	13 (59.1)	15 (68.2)	.0573
NIV (%)	0 (0)	0 (0)	0 (0)	.607
CPAP (%)	1 (3.6)	5 (22.7)	5 (22.7)	.0884
Ventilator (%)	0 (0)	4 (18.2)	7 (31.8)	.00729
ECMO (%)	0 (0)	0 (0)	1 (4.5)	.316
Pressor drugs (%)	0 (0)	3 (13.6)	7 (31.8)	.00543
Dialysis (%)	0 (0)	1 (4.5)	3 (13.6)	.109
Kidney failure (%)	0 (0)	2 (9.1)	3 (13.6)	.152
Liver failure (%)	0 (0)	2 (9.1)	1 (4.5)	.278
Lung failure (%)	1 (3.6)	4 (18.2)	8 (36.4)	.0114
Heart failure (%)	0 (0)	2 (9.1)	0 (0)	.0966
Died (%)	0 (0)	4 (18.2)	2 (9.1)	.0687

Abbreviations: CPAP, continuous positive airway pressure; ECMO, extra-corporal-membrane-oxygenation; NIV, non-invasive ventilation; suPAR, soluble urokinase Plasminogen Activator Receptor.

Abbreviations: CPAP, continuous positive airway ventilation; CRP, C-reactive protein; ECMO, extra corporal membrane oxygenation; NIV, non-invasive ventilation; suPAR, soluble urokinase Plasminogen Activator Receptor.

Bonferroni-corrected significance level = .003. Data are shown N (%).